Enhanced antitumor efficacy of doxorubicin-encapsulated halloysite nanotubes

Abstract

To improve the antitumor efficacy of doxorubicin (DOX) and provide novel clinical treatment of gastric cancer, halloysite nanotubes (HNTs) loaded with DOX were encapsulated by soybean phospholipid (LIP) and the formed HNTs/DOX/LIP was systematically characterized via different techniques. The in vitro anticancer activity of HNTs/DOX/LIP was examined using an MTT assay. The antitumor efficacy and biocompatibility were monitored by measuring the tumor volume and assessing the blood routine and serum biochemistry using an ectopic implantation cancer model. The results show that when the concentration of HNTs was 3 mg/mL and the concentration of DOX was 1 mg/mL the optimal DOX loading efficiency was as high as 22.01%±0.43%. In vitro drug release behavior study demonstrated that HNTs/DOX/LIP shows a pH-responsive release property with fast drug release under acidic conditions (pH =5.4). MTT assays and in vivo experimental results revealed that HNTs/DOX/LIP exhibits a significantly higher inhibitory efficacy on the growth of mouse gastric cancer cells than free DOX at the same drug concentration. In addition, the life span of tumor-bearing mice in the HNTs/DOX/LIP-treated group was obviously prolonged compared with the control groups. Moreover, HNTs/DOX/LIP possessed excellent hemocompatibility as shown in the blood and histology studies. These findings indicated that the formed HNTs/DOX/LIP possesses higher antitumor efficacy and may be used as a targeted delivery nanoplatform for targeting therapy of different types of cancer cells.

Citrate- and Succinate-Modified Carbonate Apatite Nanoparticles with Loaded Doxorubicin Exhibit Potent Anticancer Activity against Breast Cancer Cells

“…Recently, halloysite nanotubes (HNTs) received much attention due to their larger surface area, non-toxicity and good thermal stability. Apart from this, HNTs can easily encapsulate drugs and can sustain the drug release by preventing rapid enzymatic degradation in vivo [ 45 , 46 ]. Li et al [ 46 ] modified HNTs with soybean phospholipid to generate HNTs/DOX/LIP complexes and noticed almost 22.01% ± 0.43 DOX loading efficiency for HNTs and HNTs/DOX/LIP.…”

“…Apart from this, HNTs can easily encapsulate drugs and can sustain the drug release by preventing rapid enzymatic degradation in vivo [ 45 , 46 ]. Li et al [ 46 ] modified HNTs with soybean phospholipid to generate HNTs/DOX/LIP complexes and noticed almost 22.01% ± 0.43 DOX loading efficiency for HNTs and HNTs/DOX/LIP. However, HNTs negatively charged surface (−16.5 ± 1.2 mV) requires positively charged drugs to bind, restricting the binding opportunity for negatively charged drugs.…”

One Pot Doxorubicin Partitioning and Encapsulation on Silica Nanoparticle, Applying Aqueous Two Phase System for Preparation of pH-Responsive Nanocarriers

“…The last mass reduction starting at 489℃ could be mainly related to DOX decomposition [95][96][97] .…”

Selective Cytotoxic Activity of Prodigiosin@halloysite Nanoformulation

“…Limited aqueous solubility of prodigiosin result in poor absorption and low bioavailability (Tran et al, 2019), as well as it may disturb regular distribution of prodigiosin in biological fluids. Bioavailability of prodigiosin can be enhanced similarly, as reported previously for anticancer drug doxorubicin (Li et al, 2017) and curcumin (Ni et al, 2019), employing fabrication of nanoscale drug formulations to overcome the limitations caused by the intrinsic hydrophobicity prodigiosin. Recently, a technique of prodigiosin encapsulation was developed and anticancer effect of targeted nanoformulations of prodigiosin was investigated (Zhao et al, 2019).…”